Enumeral Biomedical Holdings Inc

Enumeral Biomedical — Investor Presentation (October 2016)

27 slides from Enumeral Biomedical's investor presentation, Oct 28, 2016

  1. Slide 1: Enumeral Overview October 2016

    Enumeral Overview October 2016 OTCQB: ENUM

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward - looking statements that are based on the company’s current expectations, assumptions, estimates and projections about the company and the pharmaceutical industry . The company makes no representations about the accuracy of such statemen

  3. Slide 3: Company Highlights

    Company Highlights • Enumeral is a biotechnology company u tilizing a patented platform to identify novel therapeutics and advance treatments in cancer and other diseases mediated by the immune system • Platform is based on technology exclusively licensed from MIT • Enumeral’s platform has been vali

  4. Slide 4: What's New

    What’s New • New Management • Wael Fayad appointed Chairman, President, and CEO • Robert Schaub joined as Interim Head of R&D • New Direction • Focus on partnerships and strategic collaborations • Focus on exploiting platform across therapeutic areas and applications • Focus on discovery to build ow

  5. Slide 5: New Leadership

    New Leadership Recently Appointed Wael Fayad • Appointed Chairman, President and CEO in September 2016 • > 20 years of executive and business experience in pharma • 14 years business development track record • Head of business development at Forest Laboratories Inc. • Secured transactions and collab

  6. Slide 6: Strengthened Management Team

    Strengthened Management Team 6 Wael Fayad Chairman, President and CEO Bob Schaub, Ph.D. Interim Head of Research and Development • 35 years scientific and executive leadership in pharma and biotech • Expert in translational drug discovery and development of small molecules and biologics • Author of

  7. Slide 7: Point Plan To Create Near Term Value

    4 Point Plan To Create Near Term Value • Prioritize strategic collaborations and partnerships to realize the potential of our platform for discovery and development of novel therapeutics • Advance pipeline to near term value inflection points • Secure funding to support plan execution • Position com

  8. Slide 8: Growth Strategy

    Growth Strategy • Raise growth capital • Further invest in discovery engine and build a deeper pipeline of therapeutics for high value targets • Close additional transformative deals • Up - list to Nasdaq 8 Focus on Creation of Shareholder Value

  9. Slide 9: Warrant exercise/amendment foundation for potential success

    Warrant exercise/amendment foundation for potential success 9 Warrant Exercise and Amendment - Extend runway - Simplify capital s tructure Scenario 1 Institutional round and NASDAQ listing Scenario 2 Interim Financing Deal Flow - Key to value creation Institutional round and NASDAQ listing • Multipl

  10. Slide 10: Planning for Success

    Planning for Success • Partner outreach ongoing • Institutional outreach ongoing • Interim financing outreach ongoing • R&D plan in place to advance pipeline to near term value inflection 10 x Management experience x Relationships x Deal making acumen Ingredients for Success High Energy and Motivate

  11. Slide 11: Proprietary Platform Based on Technology Exclusively Licensed from MIT

    Proprietary Platform Based on Technology Exclusively Licensed from MIT 11 84,672 50µm micro wells • Broadly enabling proprietary platform for characterization of single cells from healthy or diseased tissue – Isolation – Identification – Characterization Measures key parameters of response of indivi

  12. Slide 12: Tissue Biopsy Approach Drives Translational Research

    Tissue Biopsy Approach Drives Translational Research 12 function phenotype genomics Integrated single cell functional profiling Biopsy Proprietary translational biology platform that uses tissue biopsies After Tsioris et al 2015 Approach Enables Our Scientists to Validate, Screen and Select Therapeu

  13. Slide 13: Strategic Focus: Drive Value and Build Pipeline

    Strategic Focus: Drive Value and Build Pipeline 13 Solid Foundation for Future Success Discovery • Enumeral’s platform has competitive advantage in discovery and development phases o Exploit full range of potential collaborations to fund business and validate science o Focus on discovery to build ow

  14. Slide 14: Validation from Respected Partners

    Validation from Respected Partners* • Pieris Pharmaceuticals – Non - exclusive license agreement • MD Anderson Cancer Center – Co - development agreement • National Cancer Institute – Initially deployed at MGH/ Ragon – Now deployed at Wolchok Lab at Memorial Sloan Kettering • Merck – Research study

  15. Slide 15: Pipeline with Multiple Opportunities

    Pipeline with Multiple Opportunities 15 PD - 1 Antibody* ENUM 244C8 PD - 1 Antibody ENUM 388D4 TIM - 3 Antibody CD39 Lead generation Screening Optimization / Differentiation Pre - Clinical Clinical IND Enabling IND Enabling Ready IND Other targets *See Appendix for additional details

  16. Slide 16: Platform with Multiple Applications

    Platform with Multiple Applications • Characterization of patient derived samples to identify – New targets – Differentiation of therapeutic agents – Clinical status – Drug development strategies • Identification of novel and diverse antibodies for – Therapeutic intervention – Diagnostics • Characte

  17. Slide 17: Near Term Milestones

    Near Term Milestones • Generate robust deal flow – Strategic platform based collaborations – Multiple assets to partner – Two assets of PD - 1, C8 and D4, can be partnered together or separately for different indications – TIM - 3 - can be partnered together or separately for multiple indications •

  18. Slide 18: Significant Value Often Recognized at Pre-Clinical Stage

    Significant Value Often Recognized at Pre - Clinical Stage • Discovery and early stage biotechs can have high valuations ‒ CTMX: ~$600M market cap ‒ RGNX: ~$400M market cap • Lucrative deals recently made at the pre - clinical stage ‒ Jounce/Celgene, July 2106 ‒ $225 million upfront + downstream ‒ Z

  19. Slide 19: Key Takeaways

    Key Takeaways • Enumeral science works and has potential to create significant value – Deal flow – D ata flow – Institutional capital • Enumeral now has right management and right plan – Experience to execute business plan – Relationships to attract corporate partners and institutional investors • W

  20. Slide 20: Thank You

    Thank You Contact: Wael Fayad Chairman, President, and CEO 200 Cambridge Park Drive Cambridge, MA, 02140 wael@enumeral.com O: 617 - 500 - 1613

  21. Slide 21: Appendix

    Appendix

  22. Slide 22: Financial Summary

    Financial Summary Category Common Shares Outstanding 52,073,481 W arrants Outstanding 24,803,409 * Options Outstanding 6,814,841 ** Cash and Cash Equivalents $1.1M *** 22 OTCQB: ENUM Price: $0.18 Market Cap $9.37M Financial Information & Capitalization (As of June 30, 2016, unless otherwise noted) *

  23. Slide 23: Experienced Board of Directors

    Experienced Board of Directors 23 Wael Fayad Chairman, President, and CEO Barry Buckland, Ph.D. Co - Founder; Director; Chairman, Scientific Advisory Board Robert J. Easton Director Allan Rothstein Director Paul J. Sekhri Director Robert L. Van Nostrand Director

  24. Slide 24: PD-1 Status Summary

    PD - 1 Status Summary • Generating stable subclone as final stage prior to generation of working and master cell bank • Initiated anti - tumor studies with Crown Bioscience PD - 1 HuGEMM model – Study 1 - Nivolumab dose response to identify no effect and “low” effect dose for study 2 comparison to E

  25. Slide 25: Collaborators Provide External Recognition of Differentiated Approach

    Collaborators Provide External Recognition of Differentiated Approach • MERCK : December 2014 collaboration with a leading immuno - oncology pharmaceutical company – Focused on using Enumeral's platform to interrogate the tumor microenvironment in colorectal cancer tissues to identify functional cel

  26. Slide 26: Collaboration with MD Anderson Cancer Center – January 2016

    Collaboration with MD Anderson Cancer Center – January 2016 • Goal to Discover and Develop Novel Antibodies Against Specified Immunotherapy Targets – Utilizes Enumeral’s antibody discovery and patient - centric immune profiling platform – Leverages MD Anderson’s preclinical and development expertise

  27. Slide 27: License and Transfer Agreement with Pieris Pharmaceuticals – Spring 2016

    License and Transfer Agreement with Pieris Pharmaceuticals – Spring 2016 • Non - exclusive license under specified Enumeral patent rights and know - how to research, develop and market fusion proteins that comprise a moiety derived from Enumeral’s 388D4 anti - PD - 1 antibody linked to one or more P

Enumeral Biomedical Holdings — Investor Presentation (October 2016) on 6ix